$BURU
Nuburu, Inc. Stock $buru

$buru Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000095017024044503 Filed on April 15, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue	$49.28K	$374.7K	$2.086M
YoY Change	-95.32%	-12.85%	44.83%
Cost Of Revenue	$733.7K	$882.0K	$5.695M
YoY Change	-70.48%	-27.1%	17.19%
Gross Profit	-$684.4K	-$507.3K	-$3.610M
YoY Change	-52.18%	-34.12%	5.55%
Gross Profit Margin	-1388.95%	-135.37%	-173.09%
Selling, General & Admin		$3.287M	$12.76M
YoY Change		152.84%	111.66%
% of Gross Profit
Research & Development	$683.4K	$1.163M	$5.463M
YoY Change	-57.8%	-37.5%	20.06%
% of Gross Profit
Depreciation & Amortization	$132.6K	$135.9K	$505.9K
YoY Change	34.12%	94.19%	12.42%
% of Gross Profit
Operating Expenses	$2.721M	$4.449M	$18.23M
YoY Change	-45.68%	41.25%	72.27%
Operating Profit	-$3.406M	-$4.957M	-$21.84M
YoY Change	-47.12%	26.45%	1014.84%
Interest Expense	$941.6K	-$553.9K	-$637.2K
YoY Change	7503.47%	515.49%	390.14%
% of Operating Profit
Other Income/Expense, Net	$218.2K	$763.9K	$1.767M
YoY Change	-34.72%		-86.87%
Pretax Income	-$12.69M	-$4.747M	-$20.71M
YoY Change	107.76%	18.08%	-280.06%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$12.69M	-$4.747M	-$20.71M
YoY Change	107.76%	18.08%	-285.85%
Net Earnings / Revenue	-25746.56%	-1266.7%	-992.86%
Basic Earnings Per Share	-$7.60		-$0.63
Diluted Earnings Per Share	-$7.60	-$0.13	-$0.63
COMMON SHARES
Basic Shares Outstanding	36.93M	35.57M	33.06M
Diluted Shares Outstanding	1.670M		33.06M

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments		$2.149M	$2.149M
YoY Change		-25.39%	-25.39%
Cash & Equivalents	$117.2K	$2.149M	$2.149M
Short-Term Investments
Other Short-Term Assets	$6.00	$206.3K	$206.3K
YoY Change	-99.92%	1640.88%	-95.21%
Inventory	$1.526M	$1.456M	$1.456M
Prepaid Expenses
Receivables	$73.28K	$482.3K	$482.3K
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$2.612M	$4.294M	$4.294M
YoY Change	-69.6%	4914.38%	-49.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.344M	$6.237M	$6.237M
YoY Change	23.19%	65.36%	35.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$34.36K	$34.36K	$34.36K
YoY Change	0.0%	0.0%	14.53%
Total Long-Term Assets	$5.776M	$6.272M	$6.272M
YoY Change	15.96%	-81.02%	35.45%
TOTAL ASSETS
Total Short-Term Assets	$2.612M	$4.294M	$4.294M
Total Long-Term Assets	$5.776M	$6.272M	$6.272M
Total Assets	$8.387M	$10.57M	$10.57M
YoY Change	-38.2%	-68.1%	-19.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.675M	$4.745M	$4.745M
YoY Change	39.74%	6.46%	6.38%
Accrued Expenses	$4.317M	$3.106M	$3.106M
YoY Change	172.41%	34.32%	16.76%
Deferred Revenue	$24.00K	$30.40K
YoY Change	-86.67%	-82.99%
Short-Term Debt		$2.148M	$2.148M
YoY Change		-70.58%	-70.58%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$13.50M	$10.03M	$10.03M
YoY Change	118.33%	-71.04%	-31.26%
LONG-TERM LIABILITIES
Long-Term Debt		$6.713M	$6.713M
YoY Change
Other Long-Term Liabilities		$2.476M	$2.476M
YoY Change		569.16%	569.16%
Total Long-Term Liabilities		$9.189M	$9.189M
YoY Change		2383.55%	2383.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.50M	$10.03M	$10.03M
Total Long-Term Liabilities		$9.189M	$9.189M
Total Liabilities	$19.34M	$19.22M	$19.22M
YoY Change	42.32%	-60.6%	28.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$100.3M	-$81.90M
YoY Change	39.16%	334.1%
Common Stock	$325.00	$3.689K
YoY Change	-90.79%	242.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$10.95M	-$8.653M	-$8.653M
YoY Change
Total Liabilities & Shareholders Equity	$8.387M	$10.57M	$10.57M
YoY Change	-38.2%	-68.1%	-19.47%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$12.69M	-$4.747M	-$20.71M
YoY Change	107.76%	18.08%	-285.85%
Depreciation, Depletion And Amortization	$132.6K	$135.9K	$505.9K
YoY Change	34.12%	94.19%	12.42%
Cash From Operating Activities		-$4.281M	-$17.54M
YoY Change		45.61%	1384.45%
INVESTING ACTIVITIES
Capital Expenditures		$24.84K	$1.168M
YoY Change		-90.45%	116.25%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		-$24.84K	-$1.168M
YoY Change		-90.45%	-100.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$2.112M
YoY Change			-99.3%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		4.828M	17.98M
YoY Change		137.82%	-105.95%
NET CHANGE
Cash From Operating Activities		-4.281M	-17.54M
Cash From Investing Activities		-24.84K	-1.168M
Cash From Financing Activities		4.828M	17.98M
Net Change In Cash		522.0K	-731.6K
YoY Change		-144.61%	54.03%
FREE CASH FLOW
Cash From Operating Activities		-$4.281M	-$17.54M
Capital Expenditures		$24.84K	$1.168M
Free Cash Flow		-$4.306M	-$18.71M
YoY Change		34.56%	986.66%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001814215
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39489
CY2023	dei	Entity Registrant Name EntityRegistrantName	NUBURU, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1288435
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	7442 S Tucson Way
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 130
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Centennial
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80112
CY2023	dei	City Area Code CityAreaCode	720
CY2023	dei	Local Phone Number LocalPhoneNumber	767-1400
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	BURU
CY2023	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	23600000
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	36932403
CY2023	dei	Auditor Name AuditorName	WithumSmith+Brown, PC
CY2023	dei	Auditor Location AuditorLocation	East Brunswick, New Jersey
CY2023	dei	Auditor Firm AuditorFirmId	100
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2148700
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2880254
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	482279
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	327200
CY2023Q4	buru	Allowances For Inventory AllowancesForInventory	1133457
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	23237703
CY2022Q4	buru	Allowances For Inventory AllowancesForInventory	292990
CY2023Q4	us-gaap	Inventory Net InventoryNet	1456275
CY2022Q4	us-gaap	Inventory Net InventoryNet	972695
CY2023Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	50000
CY2022Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	4258515
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	156255
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	46737
CY2023Q4	us-gaap	Assets Current AssetsCurrent	4293509
CY2022Q4	us-gaap	Assets Current AssetsCurrent	8485401
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5650976
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3771849
CY2023Q4	buru	Construction In Progress Noncurrent ConstructionInProgressNoncurrent	0
CY2022Q4	buru	Construction In Progress Noncurrent ConstructionInProgressNoncurrent	188912
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	586164
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	641651
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	34359
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	34359
CY2023Q4	us-gaap	Assets Assets	10565008
CY2022Q4	us-gaap	Assets Assets	13122172
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4744606
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4456587
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2750305
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2312118
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	355385
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	343049
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	30400
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	178750
CY2023Q4	buru	Note Payable Current NotePayableCurrent	2147992
CY2022Q4	buru	Note Payable Current NotePayableCurrent	0
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	7300000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10028688
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14590504
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	237369
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	373907
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	6713241
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0
CY2023Q4	buru	Warrant Liabilities Non Current WarrantLiabilitiesNonCurrent	2238519
CY2023Q4	us-gaap	Liabilities Liabilities	19217817
CY2022Q4	us-gaap	Liabilities Liabilities	14964411
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2388905
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2388905
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	23237703
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	239
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	4040
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36894323
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36894323
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5556857
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5556857
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3689
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1077
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	73241955
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	59344952
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-81898692
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-61192308
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-8652809
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1842239
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10565008
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13122172
CY2023	us-gaap	Revenues Revenues	2085532
CY2022	us-gaap	Revenues Revenues	1440428
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	5695433
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	4859599
CY2023	us-gaap	Gross Profit GrossProfit	-3609901
CY2022	us-gaap	Gross Profit GrossProfit	-3419171
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5462680
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4546057
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1539690
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	708144
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11223449
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5324417
CY2023	us-gaap	Operating Expenses OperatingExpenses	18225819
CY2022	us-gaap	Operating Expenses OperatingExpenses	10578618
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-21835720
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-13997789
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	117372
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	43976
CY2023	us-gaap	Interest Expense InterestExpense	754549
CY2022	us-gaap	Interest Expense InterestExpense	175288
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1766513
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20706384
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14129101
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20706384
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14129101
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.63
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.63
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.59
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.59
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33064250
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33064250
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5458184
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5458184
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	9588075
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	188890
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	147557
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2362340
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14129101
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1842239
CY2023	buru	Issuance Of Common Stock And Series A Preferred Stock Upon Conversion Of Convertible Notes In Connection With The Reverse Recapitalization IssuanceOfCommonStockAndSeriesAPreferredStockUponConversionOfConvertibleNotesInConnectionWithTheReverseRecapitalization	11575286
CY2023	buru	Issuance Of Common Stock And Preferred Stock Upon Reverse Recapitalization Net Of Issuance Costs IssuanceOfCommonStockAndPreferredStockUponReverseRecapitalizationNetOfIssuanceCosts	-3257525
CY2023	buru	Recognition Of Public Warrants Upon The Reverse Recapitalization RecognitionOfPublicWarrantsUponTheReverseRecapitalization	-1336863
CY2023	buru	Issuance Cost From Issuance Of Common Stock Warrants IssuanceCostFromIssuanceOfCommonStockWarrants	160345
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2351414
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6999
CY2023	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-33903
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2490409
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20706384
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-8652809
CY2023	us-gaap	Profit Loss ProfitLoss	-20706384
CY2022	us-gaap	Profit Loss ProfitLoss	-14129101
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	505898
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	450505
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	2490409
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2362340
CY2023	buru	Changes In Fair Value Adjustment Of Warrants ChangesInFairValueAdjustmentOfWarrants	-1766513
CY2023	buru	Inventory Reserve Adjustment InventoryReserveAdjustment	840467
CY2022	buru	Inventory Reserve Adjustment InventoryReserveAdjustment	-258116
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	416636
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	105924
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	155079
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	103925
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1613781
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	199429
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	268118
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-23336
CY2023	buru	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-319426
CY2022	buru	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-292932
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2715504
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	628702
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	111939
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1013437
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-148350
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	5700
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-388141
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-314111
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17540163
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10227730
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1167751
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	536038
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1167751
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-536038
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	4100000
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	7300000
CY2023	buru	Proceeds From Issuance Of Senior Convertible Notes And Warrants ProceedsFromIssuanceOfSeniorConvertibleNotesAndWarrants	9225000
CY2023	buru	Proceeds From Issuance Of Junior Notes And Warrants Net Of Discount ProceedsFromIssuanceOfJuniorNotesAndWarrantsNetOfDiscount	5000000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6999
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	147557
CY2023	buru	Restricted Stock Units Used For Tax Withholdings RestrictedStockUnitsUsedForTaxWithholdings	33903
CY2022	buru	Proceeds From Issuance Of Preferred Stock ProceedsFromIssuanceOfPreferredStock	188890
CY2023	buru	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	3243079
CY2023	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	5000
CY2023	buru	Payment Of Transaction Costs Related To Reverse Recapitalization PaymentOfTransactionCostsRelatedToReverseRecapitalization	4734913
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	675000
CY2023	buru	Payment Of Deferred Financing Costs PaymentOfDeferredFinancingCosts	259899
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17976360
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7636447
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-731554
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3127321
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2880254
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6007575
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2148700
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2880254
CY2023	buru	Right Of Use Assets Obtained In Exchange For New Operating Lease Liabilities RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities	263939
CY2022	buru	Right Of Use Assets Obtained In Exchange For New Operating Lease Liabilities RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities	934583
CY2023	buru	Property And Equipment Transferred From Inventory PropertyAndEquipmentTransferredFromInventory	430666
CY2023	buru	Property And Equipment Transferred From Prepaid Expenses PropertyAndEquipmentTransferredFromPrepaidExpenses	198600
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	540028
CY2023	buru	Deferred Financing Costs Included In Accounts Payable And Accrued Expenses DeferredFinancingCostsIncludedInAccountsPayableAndAccruedExpenses	681845
CY2022	buru	Deferred Financing Costs Included In Accounts Payable And Accrued Expenses DeferredFinancingCostsIncludedInAccountsPayableAndAccruedExpenses	4258515
CY2023	buru	Transaction Costs Related To Reverse Recapitalization Not Yet Paid TransactionCostsRelatedToReverseRecapitalizationNotYetPaid	1007439
CY2023	buru	Issuance Of Common Stock Upon Conversion Of Preferred Stock IssuanceOfCommonStockUponConversionOfPreferredStock	65
CY2023	buru	Issuance Of Common Stock Upon Conversion Of Preferred Stock In Connection With Reverse Recapitalization IssuanceOfCommonStockUponConversionOfPreferredStockInConnectionWithReverseRecapitalization	11575286
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20706384
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14129101
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-81898692
CY2023Q2	buru	Proceeds From Issuance Of Convertible Notes And Warrants ProceedsFromIssuanceOfConvertibleNotesAndWarrants	9225000
CY2023Q4	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	5500000
CY2023Q2	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	11400000
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Reclassification</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Certain prior period balances in the consolidated statements of cash flows have been combined or reclassified to conform to current period presentation pursuant to Rule 10-01(a)(2) of Regulation S-X of the SEC. Such reclassifications had no impact on net income, cash flows or shareholders' equity previously reported.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Estimates and assumptions made by management include, but are not limited to, the Company's inventory reserve and valuation of stock-based awards and warrants issued. Such estimates may be subject to change as more current information becomes available and, accordingly, the actual results could differ significantly from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Concentrations of Credit Risk, Other Risks and Uncertainties</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company's financial instruments that are subject to credit risk consist primarily of cash and cash equivalents and accounts receivable. At December 31, 2023 and 2022, substantially all of the Company's cash and cash equivalents were held in one large financial institution located in the United States. Management believes the financial risk associated with these balances is minimal and has not experienced any losses to date. The Company generally requires deposits from its customers. The Company's accounts receivable are derived from billings to customers and it has not experienced any collection issues to-date.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company's future results of operations involve a number of risks and uncertainties. The Company’s current business activities consist of business planning, research and development efforts to design and develop high-power, high-brightness blue laser technology, and capital raising to finance the Company through full commercialization. The Company is subject to the risks associated with such activities, including the need to further develop its technology and its marketing and distribution channels; further develop its supply chain and manufacturing; and hire additional management and other key personnel. Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations, are dependent upon future events, including its ability to access potential markets and secure long-term financing.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company currently depends upon a small number of customers for a substantial portion of its revenue. During the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> customers accounted for </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">39</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">29</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% of the Company's revenue, respectively. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> customers accounted for </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">47</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% of the Company’s revenue, respectively. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">four</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> customers accounted for </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%, </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%, </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%, and </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% of the Company's accounts receivable, respectively. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> customers accounted for </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">62</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%, </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">%, and </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% of the Company’s accounts receivable, respectively. Loss of any of the Company's customers could have a material adverse effect on the Company's operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31323904
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31323904
CY2023	buru	Proceeds From Business Combination ProceedsFromBusinessCombination	3200000
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1973634
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1011421
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	158346
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	15213
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	457752
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	239051
CY2023Q4	us-gaap	Inventory Gross InventoryGross	2589732
CY2022Q4	us-gaap	Inventory Gross InventoryGross	1265685
CY2023Q4	us-gaap	Inventory Adjustments InventoryAdjustments	1133457
CY2022Q4	us-gaap	Inventory Adjustments InventoryAdjustments	292990
CY2023Q4	us-gaap	Inventory Net InventoryNet	1456275
CY2022Q4	us-gaap	Inventory Net InventoryNet	972695
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	640000
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	250000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8480860
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5954903
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2829884
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2183054
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5650976
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3771849
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	505898
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	450505
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	61342
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	94653
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	34889
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	260
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	11848
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	156255
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	46737
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	754904
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	636009
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	838865
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	548569
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	263939
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	934584
CY2023Q4	buru	Accrued Transaction Costs Related To Reverse Recapitalization Current AccruedTransactionCostsRelatedToReverseRecapitalizationCurrent	503600
CY2022Q4	buru	Accrued Transaction Costs Related To Reverse Recapitalization Current AccruedTransactionCostsRelatedToReverseRecapitalizationCurrent	651818
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	89346
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	108516
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	337913
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	175288
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	225677
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	191918
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2750305
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2312118
CY2023	buru	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	buru	Stock Price Per Share StockPricePerShare	11.5
CY2023Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	0
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	352080
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	340146
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y6M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.055
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	372214
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	361324
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	383383
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	240834
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	624217
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	31463
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	592754
CY2023	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	602335
CY2022	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	657112
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2085532
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1440428
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2085532
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1440428
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	223275
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	173050
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	327200
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	178750
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	482279
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	30400
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	32500
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1800
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	2751533
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	0
CY2023Q4	us-gaap	Deferred Finance Costs Current Gross DeferredFinanceCostsCurrentGross	600475
CY2022Q4	us-gaap	Deferred Finance Costs Current Gross DeferredFinanceCostsCurrentGross	0
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2147992
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	7300000
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	6713241
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	8861233
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	7300000
CY2023Q4	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.07
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	11400000
CY2023Q1	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.08
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	8.5
CY2023	buru	Convertible Preferred Stock Textblock ConvertiblePreferredStockTextblock	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">NOTE 9. CONVERTIBLE PREFERRED STOCK</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Legacy Nuburu Preferred Stock Financing</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In multiple closings in December 2021 and January 2022, Legacy Nuburu sold an aggregate of </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,166,372</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares of Legacy Nuburu Series C Preferred Stock, at a purchase price of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.00</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> per share, for an aggregate purchase price of approximately $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.8</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Series A Preferred Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Ranking</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company’s Preferred Stock ranks senior to the Company’s Common Stock with respect to rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dividends</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Holders of the Company’s Preferred Stock participate, on an as-converted basis (without regard to any conversion limitations) in all dividends paid to the holders of the Company’s Common Stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Conversion Rights</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Preferred Stock is convertible at any time into Common Stock at a conversion rate equal to $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.00</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> (subject to equitable adjustment in the event of a stock split, stock consolidation, subdivision or certain other events of a similar nature that increase or decrease the number of shares of Preferred Stock outstanding (the “Original Issuance Price”)) divided by the lesser of (i) $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.50</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> and (ii) the greater of (x) </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">115</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% of the lowest volume-weighted average price per share of the Company’s Common Stock as displayed under the heading Bloomberg VWAP (the “VWAP”) for any consecutive ninety-trading day period prior to the calculation of such VWAP and (y) $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.00</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, in each case subject to adjustment as set forth in the Certificate of Designations (the “Conversion Price”).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Any conversion will be settled only in shares of Common Stock; provided, that, upon any conversion that would result in the holders beneficially owning greater than </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.99</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% of the Company’s voting stock outstanding as of the conversion date or any individual holder beneficially owning Common Stock in excess of the maximum number of shares of Common Stock that could be issued to the holder without triggering a change of control under the applicable stock exchange listing rules, the excess, if any, of the conversion consideration otherwise payable upon such conversion shall be paid in cash, based on an amount per share of Common Stock equal to the last reported price per share of the Common Stock on the trading day immediately preceding the conversion date.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Mandatory Conversion</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">If the VWAP is greater than </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">200</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% of the Conversion Price for any </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> trading days in a </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">30-day</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> trading day period, the Company may elect to convert all, but not less than all, of the Preferred Stock then outstanding into the Company’s Common Stock at a conversion rate with respect to each share of Preferred Stock equal to the Original Issuance Price as of the date of such conversion divided by the then applicable Conversion Price.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Voting Rights</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The holders of Preferred Stock are not entitled to vote at or receive notice of any meeting of stockholders, except the holders of Preferred Stock are entitled to certain consent rights on matters related to (i) the creation or authorization of the creation of any equity or debt securities of the Company that rank senior or equal to certain rights of the Preferred Stock and (ii) the authorization of any adverse change to the powers, preferences, or special rights of the Preferred Stock set forth in the Company’s Certificate of Incorporation or Bylaws, and shall have voting rights as required by law.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Redemption</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">On the second anniversary of the Closing Date, or January 31, 2025 (the “Test Date”), the Company is obligated to redeem the maximum portion of the Preferred Stock permitted by law in cash at an amount equal to the Original Issuance Price as of such date if the Conversion Price exceeds the VWAP. If, on the Test Date, the Conversion Price is equal to or less than the VWAP, the Company must convert all shares of Preferred Stock then outstanding into shares of the Company’s Common Stock at the then applicable Conversion Price. Notwithstanding the foregoing, the Company shall not be required to redeem any shares of Preferred Stock to the extent the Company does not have legally available funds to effect such redemption. The mandatory redemption and conversion provisions described herein are further subject to certain limitations detailed in the Certificate of Designations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Series A Preferred Stock Issuances</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company is authorized to issue </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock with a par value of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> per share with such designation, rights and preferences as may be determined from time to time by the Company’s board of directors. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,388,905</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">23,237,703</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock issued or outstanding, respectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Upon the Closing of the Business Combination, all </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">23,237,703</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares of issued and outstanding convertible preferred stock were cancelled and converted into </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">23,237,703</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares of Legacy Nuburu common stock based upon the conversion rate as calculated pursuant to Legacy Nuburu's Certificate of Incorporation, multiplied by the Exchange Ratios at the Effective Time.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Additionally, upon the Closing of the Business Combination, the cancellation and conversion of all Legacy Nuburu Convertible Notes into shares of Legacy Nuburu common stock in accordance with its terms as of immediately prior to the Effective Time resulted in the issuance of </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,642,239</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares which were then outstanding as Legacy Nuburu common stock as of immediately prior to the Effective Time and subsequently converted into </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,361,787</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares of Nuburu Common Stock and </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,361,787</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares of Nuburu Series A preferred stock at the Effective Time.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">As of the Closing, each Legacy Nuburu stockholder waived its right to participate in the Preferred Stock Issuance (for clarity, excluding any shares received as a result of the conversion of any Legacy Convertible Notes prior to the Closing, which were entitled to participate in the Preferred Stock Issuance). Legacy Nuburu stockholders were entitled to receive approximately </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">99</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">% of the Common Stock issued as merger consideration pursuant to the Business Combination Agreement agreed to waive such right by entering into the Stockholder Support Agreement (for clarity, excluding any shares received as a result of the conversion of any Legacy Convertible Notes). Those Legacy Nuburu stockholders who did not waive their right to participate resulted in the issuance of </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15,478</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares of Nuburu Series A preferred stock at the Effective Time.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Each Tailwind stockholder who did not redeem their shares received a share of Nuburu Series A preferred stock. This resulted in the issuance of </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">316,188</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares of Nuburu Series A preferred stock to those non-redeeming stockholders.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Tailwind and the Tailwind Sponsor entered into the Sponsor Support and Forfeiture Agreement. In connection with the Business Combination, the </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,355,393</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> Founder Shares were forfeited other than </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,150,000</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares of Common Stock (of which, </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">150,000</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares were transferred to Nautilus Maser Fund, L.P. and </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares were transferred to Cohen & Company Capital Markets at Closing) and </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">650,000</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series A preferred stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Wilson Sonsini Goodrich & Rosati, Professional Corporation (“WSGR”) was engaged by Legacy Nuburu to act as its counsel for the Business Combination. As partial compensation for the services provided by WSGR to Legacy Nuburu in connection with the Business Combination, the Company agreed to issue to WSGR </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">195,452</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares of Common Stock and </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">195,452</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares of Preferred Stock pursuant to the terms of the Stock Purchase Agreement entered into by and between the Company and WSGR on March 10, 2023. The foregoing issuance was made in a transaction not involving a public offering pursuant to an exemption from the registration requirements of the Securities Act in reliance upon Section 4(a)(2) of the Securities Act or Regulation D promulgated under the Securities Act.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Legacy Nuburu entered into an engagement letter with Anzu Partners on August 30, 2022 pursuant to which Legacy Nuburu, in recognition of past Services, (i) agreed to pay $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> to Anzu Partners upon the closing of the Business Combination and (ii) issued a warrant with a strike price of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.01</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> per share to Anzu Partners for </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares of Preferred Stock (the “Anzu Partners Warrant”). This warrant was exercised by Anzu Partners in connection with the Closing and the $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> payment was made during the nine months ended September 30, 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Conversions</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, a holder of Series A Preferred Stock converted </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">650,000</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series A Preferred Stock to </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,300,000</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> share of Common Stock under the terms described under "Conversion Rights" above.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q1	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	10
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2490409
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2362340
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3133270
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.35
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M24D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5484316
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5315917
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.48
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	5153
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.36
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	896284
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.27
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7547750
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.86
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2954137
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.1
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y4M24D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	7547750
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.86
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y10M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M18D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.449
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.476
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.42
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.038
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.055
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.026
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4346294
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2967112
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-400290
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-767514
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	82430
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	102560
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	418321
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	73558
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-167497
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	24868
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5249972
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3680756
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	13095540
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9469767
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1647502
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1229181
CY2023Q4	buru	Deferred Tax Assets Capitalized Pre Business Expenses DeferredTaxAssetsCapitalizedPreBusinessExpenses	2229904
CY2022Q4	buru	Deferred Tax Assets Capitalized Pre Business Expenses DeferredTaxAssetsCapitalizedPreBusinessExpenses	2563946
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	124458
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	26290
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	899453
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	481062
CY2023Q4	buru	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Inventory Reserve DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsInventoryReserve	243070
CY2022Q4	buru	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Inventory Reserve DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsInventoryReserve	64726
CY2023Q4	buru	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	127116
CY2022Q4	buru	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	158388
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1905522
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	919466
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	20272565
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	14912826
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	19756671
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14506698
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	515894
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	406128
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	390191
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	264377
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	125703
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	141751
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	515894
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	406128
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023	buru	Interest Expenses Eligibility For Deduction As A Percentage Of Adjusted Earnings Before Interest And Tax Expense InterestExpensesEligibilityForDeductionAsAPercentageOfAdjustedEarningsBeforeInterestAndTaxExpense	0.30
CY2023	buru	Description Of Operating Loss Carryforwards Expiration DescriptionOfOperatingLossCarryforwardsExpiration	2035 through 2037 with the remainder having an indefinite carryforward
CY2023	buru	Percentage Of Limitations On Use For Net Operating Loss Carryforwards PercentageOfLimitationsOnUseForNetOperatingLossCarryforwards	0.80
CY2023	buru	Description Of Tax Credit Carryforward Expiration DescriptionOfTaxCreditCarryforwardExpiration	2035 through 2043
CY2023Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	19200000
CY2022Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	14500000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5300000
CY2023	buru	Minimum Percentage Increase In Ownership By Five Percent Shareholders During A Three Year Testing Period MinimumPercentageIncreaseInOwnershipByFivePercentShareholdersDuringAThreeYearTestingPeriod	0.50
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.019
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.054
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.004
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.007
CY2023	buru	Effective Income Tax Rate Reconciliation General Business Credits EffectiveIncomeTaxRateReconciliationGeneralBusinessCredits	0.02
CY2022	buru	Effective Income Tax Rate Reconciliation General Business Credits EffectiveIncomeTaxRateReconciliationGeneralBusinessCredits	0.005
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.008
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.253
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.26
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	80059578
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6602389

Files In Submission

Name	View Source	Status
0000950170-24-044503-index-headers.html	Edgar Link	pending
0000950170-24-044503-index.html	Edgar Link	pending
0000950170-24-044503.txt	Edgar Link	pending
0000950170-24-044503-xbrl.zip	Edgar Link	pending
buru-20231231.htm	Edgar Link	pending
buru-20231231.xsd	Edgar Link	pending
buru-ex10_39.htm	Edgar Link	pending
buru-ex10_40.htm	Edgar Link	pending
buru-ex10_41.htm	Edgar Link	pending
buru-ex10_42.htm	Edgar Link	pending
buru-ex10_43.htm	Edgar Link	pending
buru-ex10_44.htm	Edgar Link	pending
buru-ex10_45.htm	Edgar Link	pending
buru-ex10_46.htm	Edgar Link	pending
buru-ex10_47.htm	Edgar Link	pending
buru-ex2_2.htm	Edgar Link	pending
buru-ex31_1.htm	Edgar Link	pending
buru-ex31_2.htm	Edgar Link	pending
buru-ex32_1.htm	Edgar Link	pending
buru-ex32_2.htm	Edgar Link	pending
buru-ex4_5.htm	Edgar Link	pending
buru-ex97.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img52873173_0.jpg	Edgar Link	pending
img52873173_1.jpg	Edgar Link	pending
img52873173_2.jpg	Edgar Link	pending
img52873173_3.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
buru-20231231_htm.xml	Edgar Link	completed
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BURU
Nuburu, Inc. Stock $buru

2024 Q2 Form 10-K Financial Statement

#000095017024044503 Filed on April 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BURU Nuburu, Inc. Stock $buru

2024 Q2 Form 10-K Financial Statement

#000095017024044503 Filed on April 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BURU
Nuburu, Inc. Stock $buru